Cantor Fitzgerald Reiterates a Buy Rating on Durect Corp

By George MacDonald

In a report released today, Irina Rivkind Koffler from Cantor Fitzgerald reiterated a Buy rating on Durect Corp (NASDAQ: DRRX), with a price target of $3. The company’s shares opened today at $2.02.

Durect Corp has an analyst consensus of Strong Buy, with a price target consensus of $2.50.

The company has a one year high of $2.65 and a one year low of $0.68. Currently, Durect Corp has an average volume of 755.9k.

Like Cantor Fitzgerald`s latest rating, based on the recent corporate insider activity of 7 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of DRRX in relation to earlier this year. Most recently, in March 2015, 21 APRIL FUND LTD, a Owner at DRRX bought 1,668,800 shares for a total of $2,837,208.

According to, Koffler is a top 25 analyst with an average return of 32.3% and a 69.9% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Apricus Biosciences Inc, Sucampo Pharmaceuticals, and Obagi Medical Products.

Durect Corp is a specialty pharmaceutical company. It develops pharmaceutical products based on its proprietary drug delivery technology platforms.